Ezetimibe Effect on Bone Mineral Density and Markers of Bone Formation and Resorption

Abstract

Background

Ezetimibe, as a lipid-lowering agent, inhibits the intestinal absorption of cholesterol and decreases low-density lipoprotein cholesterol (LDL-C) level in serum. It also up-regulates hepatic cholesterol biosynthesis and, by contrast to statins, increases serum mevalonate levels. Statins and biphosphonates decrease osteoclastic activity through the same mechanisms by inhibiting the mevalonate pathway. We therefore tested the effect of ezetimibe on bone turnover in hypercholesterolemic patients.

Subject and Methods

In an open-label clinical trial, 54 hypercholesterolemic patients included in the study underwent 12 months of treatment with ezetimibe at a dosage of 10 mg/d. Before and after the 1-year ezetimibe treatment, bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry and serum samples taken for measurements of levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol and LDL-C, serum calcium (Ca), serum phosphate, total and bone alkaline phosphatases (ALPs), and carboxyterminal fragment of type 1 collagen in the serum.

Results

The hypercholesterolemic patients showed a significant reduction with respect to baseline TC and LDL-C serum levels: 20% for TC (270.18 [38.58]−214.46 [38] mg/dL) and 24% for LDL-C (189.57 [38.58]−144 [32.05] mg/dL). Biochemical markers of both bone formations (total ALP level, 65.50 [21.33]−66.27 [21.017] IU/L and bone ALP level, 55.93 [7.92]−56.25 [7.49] IU/L) and bone resorption (β-CTx, 0.44 [0.24]−0.46 [0.21] ng/mL) increased but did not show any significant change for the whole study period. At the end of 1 year, both BMD-lumbar spine (0.90 [0.12]−0.89 [0.08] g/cm²) and BMD-total femur (0.93 [0.12]−0.92 [0.12] g/cm²) showed a negative trend but without reaching statistical significance.

Conclusions

Our study results showed a negative trend but did not demonstrate statistically significant changes of BMD and metabolic markers with the treatment of ezetimibe.

Keywords

ezetimibe bone mineral density hyperlipidemia

Get full access to this article

View all access options for this article.

References

Edwards

, Russell

, Spector

TD.

Statins and bone: myth or reality?

Calcif Tissue Int. 2001;69(2):63–66.

Miwa

, Watada

, Omura

, . Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients. Endocr J. 2005;52(2):259–264.

Staal

, Frith

, French

, . The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res. 2003;18(1):88–96.

Massy

, Keane

, Kasiske

. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347(8994):102–103.

Mundy

, Garrett

, Harris

, . Stimulation of bone formation in vitro and in rodents by statins science. 1999;286(5446):1946–1949.

Landmesser

, Bahlmann

, Mueller

, . Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111(18):2356–2363.

Safaei

, Janghorbani

, Aminorroaya

, . Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007;44(2):76–82.

Uzzan

, Cohen

, Nicolas

, . Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone. 2007;40(6):1581–1587.

, Wang

, Qi

, . The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7(6):469–471.

10.

Charlton-Menys

, Durrington

Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93(1):27–42.

11.

Välimäki

, Farrerons-Minguella

, Halse

, . Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007;29(9):1937–1949.